PASS OCT® Post-market Clinical Follow-up
Prospective, multicenter non comparative and observational study (post-market clinical follow-up).

Patients operated with PASS OCT® manufactured by MEDICREA® INTERNATIONAL between July 2016 and July 2017.

The inclusion period will be 12 months and the follow-up 24 months
Intervertebral Disc Disease|Spondylolisthesis|Spinal Stenosis|Spinal Neoplasms|Spinal Fractures
DEVICE: PASS OCT® Spinal System
Adverse events, To quantify and describe adverse events, 12 months postoperatively
Fusion, Radiological assessment of bony fusion, 1-6 months, 12 months, 24 months postoperatively|Disability, To assess disability using NDI score, 1-6 months, 12 months, 24 months postoperatively|Quality of life, To assess quality of life through mJOA scoring system, 1-6 months, 12 months, 24 months postoperatively|Pain, To assess pain using visual analogue scale, 1-6 months, 12 months, 24 months postoperatively
The primary endpoint is to evaluate the safety of the PASS OCT® system.

The secondary endpoints are to analyze the efficacy of the system with several point of view:

* The quality of fusion and the time of fusion through X rays
* the pain with VAS
* the quality of life thanks to questionnaires: NDI (Neck Disability Index) and JOA for myelopathy
* the daily of the patient: return to work, sport
* the surgeon satisfaction.